SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M /Undiscovered Stock/ Lots of Marketed Products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..Please do your own dd and realize the Monster Potential here .Thank me later
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Im actually beginning to think the market for ABSSSI /MRSA may be twice as large as for CABP. 119,000 deaths for MRSA 59,000 for CABP. If Baxdella has twice the sales potential as Soli and we own half,then share price should be worth above $25 today.
Woohoo! Trading halted. Still have some calls in CEMP. Will I be retiring early? LOL
Where's the bottom on this. Seems to me Melinta is getting a pretty good deal here. I think the real value in this merger is about 90% Melinta. Not sure why they didn't just go IPO on their own though. Market Cap now $152M. Seems too low to me.
Does anyone here who is smarter than me have any idea what longs should do here? What would be a good move for people holding calls? The markets reaction to the news today is hard to translate.
Way oversold. We are going to go back up over next few weeks.
Market reaction is crazy IMO.The combined value is worth more than the entities. The value of Melinta is substantial. Overhead will be halved for each company.One board ,one marketing staff.Multiple products .One ready to stream income.
WTH ??? hopefully a good buy opportunity.
Interesting read in edited transcript...
Merger with Melinta...looking for a new ceo...Charles, are you available?
Charles I bet you are a 140 lb. #$%$ who takes it in the #$%$.
Do we get extra new number of stock or CEMP will be replaced by new company's stock.
Soli treats those with unmet needs.Risk/benefit has already been established as beneficial. Im liking our chances. "This philosophy reflects the FDA’s commitment to expediting the availability of drugs for serious diseases for patients as soon as it can be concluded that the drug’s benefits exceed its risks, especially when these patients have unmet needs, while preserving appropriate standards for safety and effectiveness. "
A reverse takeover or reverse merger takeover (reverse IPO) is the acquisition of a public company by a private company so that the private company can bypass the lengthy and complex process of going public. The transaction typically requires reorganization of capitalization of the acquiring company.
check out mbrx... big news today
cannot an accurate and precise liver test result be achieved in a smaller sample set? a standard starts showing itself at say 1000 subjects the same as 2000 subjects.